Novel Suppository Design for HIV Chemoprophylaxis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novel Suppository Design for HIV Chemoprophylaxis
Technical Note: The authors investigated the variables important for calcium-alginate formation as well as dissolution.


Pharmaceutical Technology
Volume 34, Issue 7, pp. 68-69, 72

Results and conclusion


Figure 1: Dissolution in citrate of 0.5 and 2.0% calcium-alginate gels containing aurintricarboxylic acid (1 mg/mL). (FIGURES ARE COURTESY OF T.J. SMITH)
Within the range of calcium and alginate tested, alginate was confirmed as the most important formulation variable in this system and was associated with the greatest change in dissolution time (see Figures 1 and 2). Variation in calcium yielded little change in the dissolution time (see Figure 2).


Figure 2: Effect of calcium chloride on the citrate-mediated dissolution of 0.5 and 2.0% alginate gels. The citrate concentration was 132 mM.
Although a single concentration of ATA was used, variations in the concentration of this polyanion must be considered if ATA and its derivatives are to be advanced for preclinical or clinical evaluation. Nevertheless, these results reflect the importance of alginate-concentration changes, regardless of the anti-HIV agent under consideration. The results also verified the importance of citrate concentration because dissolution time appeared to be inversely proportional to citrate concentration (see Figure 1). Citrate in seminal fluid at a concentration of ~132 mM) is reduced by as much as 50% in certain disease processes (7). While this reduction in citrate would be expected to decrease the release rate of drug from the formulation, total dissolution occurred at both citrate concentrations. Microgranular cellulose yielded suppositories of a prototype that may yield sustained-release characteristics in the presence of citrate. The properties of the suppositories and the dissolution time are summarized in Table I.


Table I: Characteristics of manually fabricated prototype suppositories.
In addition to its utility to viscosity enhancement for manual fabrication of the prototype suppositories, cellulose is relatively inexpensive and safe to use for intravaginal and intrarectal applications (4, 5). This formulation's capability to alter release rates for anti-HIV drugs, as well as the simplicity of design, deserves further consideration and investigation.

Timothy J. Smith* is a professor and chair of the Department of Physiology and Pharmacology, and Lara Haddad, Soraia Faizyar, Evelyn Valdez, Elizabeth Gramer, Layla S. Derreja, and Stefany M. Bowers are doctoral students, all at Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, tel. 209.946.3168, fax 209.946.2857,
.

*To whom all correspondence should be addressed.

Submitted: Aug. 25, 2009. Accepted: Oct. 7, 2009.

References

1. K. Fong and T.J. Smith, Pharm. Dev. Technol. 14 (4), 341–342 (2009).

2. M. Cushman et al., J. Med. Chem. 34 (1), 329–337 (1991).

3. J. LaBonte, J. Lebbos, and P. Kirkpatrick, Nat. Rev. Drug Discov. 2 (5), 345–346 (2003).

4. A.R. Neurath, N. Engl. J. Med. 359 (19), 2066–2067 (2008).

5. V.M.K. Ndesendo et al., AAPS PharmSciTech. 9 (2), 505–520 (2008).

6. T.J. Smith, Curr. Top. Biotechnol. 1, 129–132 (2004).

7. E.E. Kline et al., J. Urol. 176 (5), 2274–2279 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here